The Evolution of STI Testing: A Catalyst for Modern Diagnostic Technologies
Case Study: HIV Diagnostics—40 Years of Innovation from Laboratory to Self-Testing
F irst identified in 1983, Human Immuno- deficiency Virus (HIV) remains one of the world’s most consequential and enduring infectious diseases, responsible for an estimated 40 million deaths to date. As of 2022, nearly 39 million people were living with HIV, two-thirds of them in sub-Saharan Africa. While HIV-1 accounts for most infections, HIV-2 remains largely confined to West Africa. In 2014, the United Nations set an ambitious goal to end the HIV epidemic by 2030, 1 highlighting the essential role of accurate and accessible diagnostics in identifying those living with the virus. Early detection sits at the heart of prevention, treatment and global surveillance efforts. This need has fueled decades of progress in HIV testing, from early laboratory-based assays to rapid, high-sensitivity molecular and
immunoassay platforms that support screening and monitoring at scale. From the first HIV antibody assay introduced in 1985 (which was initially used to screen blood donations rather than diagnose infections) 2 to today’s rapid molecular and immunoassay solutions, continual innovation has transformed HIV diagnostics. Advances in assay design, enzyme chemistry and detection sensitivity have shortened the seroconversion window and improved usability, while extending access beyond centralized laboratories to point-of-care and self-testing formats. Today, HIV serves as a model for how diagnostic technology can evolve from the lab bench to the living room, enabling faster diagnosis, greater accessibility and more personalized patient care worldwide.
GENengnews.com | 27
Powered by FlippingBook